ZURICH, April 15 Adverse currency moves weighed
on first-quarter sales at Roche Holding AG, which fell
1 percent, despite a healthy uptake of its new cancer medicines.
The world's largest maker of cancer drugs said first quarter
sales were 11.5 billion Swiss francs ($13.08 billion), slightly
below the average analyst forecast of 11.89 billion in a Reuters
A weak U.S. dollar, Japanese yen and Latin American
currencies took a toll, shaving 6 percentage points off
first-quarter sales. Excluding the impact of currencies, sales
were up 5 percent.
($1 = 0.8791 Swiss Francs)
(Reporting by Caroline Copley)